ARCA biopharma, Inc. — Q1 2017 Form 10-Q
Filing identity: The supplied filing is for ARCA biopharma, Inc., not Oruka Therapeutics, Inc. It covers the quarter ended March 31, 2017; the financial statements are unaudited.
Business context
ARCA is a clinical-stage biopharmaceutical company developing Gencaro (bucindolol hydrochloride), an investigational therapy for atrial fibrillation in patients with heart failure and reduced ejection fraction. Its GENETIC-AF trial compares Gencaro with TOPROL-XL in patients selected for a specific genotype. The company reported no revenue to date and had no approved products.
Financial performance and liquidity
| Metric | Q1 2017 | Q1 2016 or prior date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $3.246 million | $2.594 million |
| General and administrative expense | $1.135 million | $1.074 million |
| Total costs and expenses | $4.381 million | $3.668 million |
| Net loss | $4.338 million | $3.647 million |
| Net loss per share, basic and diluted | $0.48 | $0.40 |
| Net cash used in operating activities | $4.344 million | $3.883 million |
At March 31, 2017, cash and cash equivalents were $6.170 million and marketable securities were $13.041 million, totaling $19.211 million in cash, cash equivalents and marketable securities, versus $23.515 million at December 31, 2016. Current assets were $19.854 million and current liabilities $2.518 million. Total liabilities were $2.553 million and stockholders’ equity $18.036 million. No material debt balance is clearly presented; interest expense was $2,000 for the quarter. Operating margins are not meaningful because the company had no revenue.
Cash and cash equivalents declined $1.231 million during the quarter. Investing activities provided $3.008 million, primarily from maturities of marketable securities, while financing activities provided $105,000. The filing reports operating cash burn of $4.344 million.
Changes versus the prior comparable period
- Net loss increased by $691,000 year over year; R&D expense rose by approximately $652,000, principally because of GENETIC-AF clinical-trial activity, including site, monitoring, patient and European expansion costs.
- G&A expense increased by approximately $61,000, mainly from consulting costs, partly offset by lower share-based compensation.
- Operating cash use increased by approximately $461,000. Investing cash flow changed from $5.202 million used in Q1 2016 to $3.008 million provided in Q1 2017, reflecting purchases and maturities of marketable securities.
Outlook, risks and unusual items
- Management expected available cash, cash equivalents and marketable securities to fund operations at the projected cost structure through the end of 2017. It also stated that continuing GENETIC-AF into Phase 3 would require additional capital or a strategic transaction.
- The company randomized its 200th patient in April 2017 and projected the DSMB interim-analysis recommendation for September 2017. Possible outcomes included proceeding to Phase 3, completing the Phase 2B stage, or stopping for futility. Phase 3 enrollment to approximately 620 total patients is conditional on financing.
- The filing states that substantial doubt exists about the company’s ability to continue as a going concern for a period from one year after issuance of the financial statements. Failure to secure funding or a strategic transaction could lead to reduced or discontinued development or operations.
- Key risks include clinical efficacy and safety, enrollment and trial timing, regulatory approval for both Gencaro and its companion genetic test, reliance on CROs and other collaborators, financing needs and potential dilution, Nasdaq listing requirements, and the ability to commercialize the product if approved.
- An at-the-market equity facility authorized up to $7.3 million. By March 31, ARCA had sold 85,068 shares; the filing reports approximately $221,000 gross proceeds and approximately $69,000 net proceeds received in the period. The cash-flow statement separately shows $210,000 in issuance proceeds, $105,000 in offering costs and $105,000 net financing cash flow.
Important facts for investors to verify
- Confirm the issuer identity: this filing is ARCA biopharma, Inc., not Oruka Therapeutics, Inc.
- Review subsequent disclosures for the DSMB recommendation and GENETIC-AF progress, including whether additional financing was obtained.
- Reconcile the ATM offering proceeds and costs across the filing’s narrative, equity statement and cash-flow statement.
- Assess the cash runway against actual trial spending and the cost of any Phase 3 program.
- Track regulatory requirements and development status of the companion diagnostic, as well as Nasdaq listing compliance and potential share dilution.